Last reviewed · How we verify
NCT05825326
Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador
trial in Myeloproliferative Neoplasm in 40 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | Sociedad de Lucha Contra el Cáncer del Ecuador |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 January 2012 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across Ecuador |
Conditions studied
- Myeloproliferative Neoplasm — all drugs for Myeloproliferative Neoplasm →
- Myeloproliferative Syndrome — all drugs for Myeloproliferative Syndrome →
- Myeloproliferative Neoplasm, Unclassifiable — all drugs for Myeloproliferative Neoplasm, Unclassifiable →
- Myeloproliferative Disorders — all drugs for Myeloproliferative Disorders →
Sponsor
Sociedad de Lucha Contra el Cáncer del Ecuador — full company profile →
Who can join
18 and older, any sex, with Myeloproliferative Neoplasm or Myeloproliferative Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to evaluate the epidemiological and clinical-pathological features of Philadelphia-negative myeloproliferative neoplasms through data from medical records
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05825326
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myeloproliferative Neoplasm
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06468033 — P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk · Phase 3 · recruiting
- NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
- NCT05745285 — Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care · NA · recruiting
- NCT06553638 — Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloprolif · active not recruiting
Other Sociedad de Lucha Contra el Cáncer del Ecuador trials
Trials by the same sponsor.
- NCT05834426 — Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers · not yet recruiting
- NCT05850377 — 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas · not yet recruiting
- NCT04137666 — NRS 2002: Nutritional Screen in Cancer Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05825326 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sociedad de Lucha Contra el Cáncer del Ecuador
- Last refreshed: 27 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05825326.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing